Global Viral Vector Manufacturing Market Report and Forecast 2024-2032

Global Viral Vector Manufacturing Market Report and Forecast 2024-2032


Global Viral Vector Manufacturing Market Report and Forecast 2024-2032

The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023 and is expected to grow at a compound annual growth rate CAGR of 19.74% reaching USD 13.5 billion by 2032.

Viral vectors are biological tools that deliver genetic material into cells for therapeutic or research purposes. They are widely used in gene therapy, vaccine development, and cell and gene editing.

The major factors driving the market growth are the increasing prevalence of genetic diseases, cancer, and infectious diseases, the rising demand for gene therapy and vaccines, the technological advancements in viral vector production and purification, and the favorable regulatory and funding environment for viral vector research and development.

Global Viral Vector Manufacturing Market Drivers and Constraints

Key Drivers of global viral vector manufacturing market:
  • Increasing Prevalence of Genetic Diseases: Conditions such as hemophilia, cystic fibrosis, and muscular dystrophy are becoming more common, driving demand for gene therapies and vaccines.
  • Rising Demand for Gene Therapy and Vaccines: There's a growing need for treatments and vaccines for rare and orphan diseases like spinal muscular atrophy and Leber congenital amaurosis.
  • Growing Clinical Trials and Approvals: The market is witnessing an increase in clinical trials and approvals for gene therapies and vaccines targeting oncology, infectious diseases, and neurological disorders, including CAR-T therapy and COVID-19 vaccines.
  • Favorable Regulatory and Reimbursement Policies: Initiatives like the Breakthrough Therapy Designation and the Orphan Drug Designation support the accelerated research, development, and commercialization of gene therapies and vaccines.
Key Constraints of Global Viral Vector Manufacturing Market:
  • High Complexity and Cost of Production: Viral vector production involves intricate and costly steps, including cell culture and virus purification, which increase the overall expense.
  • Limited Availability and Scalability: The scarcity of viral vector manufacturing facilities, equipment, and skilled personnel leads to supply-demand imbalances and production bottlenecks.
  • Variability in Quality and Quantity: Inconsistencies in the quality and quantity of viral vectors can impact the safety, efficacy, and stability of gene therapy products.
  • Safety and Ethical Issues: The use of viral vectors raises concerns regarding immunogenicity, insertional mutagenesis, off-target effects, and social acceptance.
Global Viral Vector Manufacturing Market Trends and Developments

The global viral vector manufacturing market has been experiencing significant growth, driven by the increasing demand for gene therapies and vaccines. This growth is a reflection of the broader trends in biotechnology and personalized medicine, where viral vectors play a critical role in delivering genetic material into cells to treat or prevent disease. Here are some key trends and developments in this rapidly evolving market:
  • Expansion of Gene Therapy Applications: The number of gene therapy products moving through clinical trials has surged, largely due to their potential to provide long-lasting or even curative treatments for a range of diseases, including genetic disorders, certain cancers, and viral infections. This has directly impacted the demand for viral vector manufacturing capabilities, as these therapies often rely on viral vectors for effective delivery mechanisms.
  • Technological Advancements in Manufacturing: To meet the growing demand, there have been considerable investments in improving the efficiency and scale of viral vector production. Innovations in bioreactor design, purification processes, and quality control measures are enhancing yield, purity, and safety. Such advancements are crucial for reducing the cost of gene therapies and making them accessible to a broader patient population.
  • Regulatory and Reimbursement Landscape: Regulatory agencies have been adapting to the rapid advancements in gene therapy by streamlining approval processes and providing guidance specific to viral vector manufacturing. Additionally, discussions around reimbursement models for gene therapies are evolving, acknowledging the unique challenges and high upfront costs associated with these treatments. This evolving landscape is shaping market dynamics, with a focus on ensuring patient access while maintaining high safety and efficacy standards.
  • Strategic Collaborations and M&A Activities: The complex nature of viral vector manufacturing has led to a rise in strategic partnerships between biotech companies and contract development and manufacturing organizations (CDMOs). These collaborations leverage the specialized capabilities of CDMOs to accelerate the development and commercialization of gene therapies. Moreover, merger and acquisition activities are reshaping the market, as companies seek to expand their capabilities and geographic reach.
  • Focus on Rare Diseases: There is a growing emphasis on developing treatments for rare and orphan diseases, many of which are genetic in nature. Viral vector-based gene therapies offer a promising approach for these conditions, leading to a focused investment in research and development efforts targeting these diseases. This trend is not only expanding the market but also addressing significant unmet medical needs.
The global viral vector manufacturing market is positioned for continued growth and transformation, driven by the convergence of scientific innovation, regulatory evolution, and strategic industry collaborations. As the field of gene therapy progresses, the demand for high-quality viral vector production capabilities will remain a critical component in the development of new and potentially curative treatments.

Global Viral Vector Manufacturing Market Segmentation

Market Breakup by Vector Type
  • Retroviral Vectors
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Adeno-Associated Viral (AAV) Vectors
  • Herpes Simplex Viral (HSV) Vectors
  • Vaccinia Viral Vectors
  • Others
Market Breakup by Indication Type
  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Others
Market Breakup by Application
  • Gene Therapy
  • Vaccinology
  • Drug Discovery and Development
  • Others
Market Breakup by Production System
  • Baculovirus Expression System
  • Mammalian Cell Expression System
  • Insect Cell Expression System
  • Others
Market Breakup by Production Scale
  • Large-Scale Production
  • Mid-Scale Production
  • Small-Scale Production
Market Breakup by End User
  • Biopharmaceutical Companies
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Research Institutes
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Viral Vector Manufacturing Market Competitive Landscape

The competitive landscape of the biopharmaceutical contract manufacturing market in Latin America and the Middle East and Africa is fragmented, with several local and international players competing for market share. Some of the key players operating in these regions are Lonza Group AG, Thermo Fisher Scientific Inc., Catalent, Inc., Merck KGaA (MilliporeSigma), FUJIFILM Diosynth Biotechnologies, WuXi AppTec Co., Ltd., Cobra Biologics (Acquired by Pall Corporation), VGXI, Inc., Sartorius AG, Kaneka Eurogentec S.A., Vigene Biosciences, Inc., Oxford Biomedica plc, Cell and Gene Therapy Catapult, Rentschler Biopharma SE, and 4D Molecular Therapeutics.

Thermo Fisher Scientific Inc. is a US-based company that provides end-to-end services for biopharmaceutical development and manufacturing, including process development, clinical trials, commercial supply, and drug product fill and finish. Catalent, Inc. is a US-based company that specializes in advanced delivery technologies and development solutions for biologics, including cell line engineering, biologics analytical services, biomanufacturing, and bioconjugation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Viral Vector Manufacturing Market Overview
3.1 Global Viral Vector Manufacturing Market Historical Value (2017-2023)
3.2 Global Viral Vector Manufacturing Market Forecast Value (2024-2032)
4 Global Viral Vector Manufacturing Market Landscape*
4.1 Global Viral Vector Manufacturing: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Viral Vector Manufacturing: Product Landscape
4.2.1 Analysis by Vector Type
4.2.2 Analysis by Indication Type
5 Global Viral Vector Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Viral Vector Manufacturing Market Segmentation (2017-2032)
6.1 Global Viral Vector Manufacturing Market (2017-2032) by Vector Type
6.1.1 Market Overview
6.1.2 Retroviral Vectors
6.1.3 Lentiviral Vectors
6.1.4 Adenoviral Vectors
6.1.5 Adeno-Associated Viral (AAV) Vectors
6.1.6 Herpes Simplex Viral (HSV) Vectors
6.1.7 Vaccinia Viral Vectors
6.1.8 Others
6.2 Global Viral Vector Manufacturing Market (2017-2032) by Indication Type
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Genetic Disorders
6.2.4 Infectious Diseases
6.2.5 Cardiovascular Diseases
6.2.6 Neurological Disorders
6.2.7 Others
6.3 Global Viral Vector Manufacturing Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Gene Therapy
6.3.3 Vaccinology
6.3.4 Drug Discovery and Development
6.3.5 Others
6.4 Global Viral Vector Manufacturing Market (2017-2032) by Production System
6.4.1 Market Overview
6.4.2 Baculovirus Expression System
6.4.3 Mammalian Cell Expression System
6.4.4 Insect Cell Expression System
6.4.5 Others
6.5 Global Viral Vector Manufacturing Market (2017-2032) by Production Scale
6.5.1 Market Overview
6.5.2 Large-Scale Production
6.5.3 Mid-Scale Production
6.5.4 Small-Scale Production
6.6 Global Viral Vector Manufacturing Market (2017-2032) by End User
6.6.1 Market Overview
6.6.2 Biopharmaceutical Companies
6.6.3 Contract Development and Manufacturing Organizations (CDMOs)
6.6.4 Research Institutes
6.6.5 Others
6.7 Global Viral Vector Manufacturing Market (2017-2032) by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Viral Vector Manufacturing Market (2017-2032)
7.1 North America Viral Vector Manufacturing Market (2017-2032) by Vector Type
7.1.1 Market Overview
7.1.2 Retroviral Vectors
7.1.3 Lentiviral Vectors
7.1.4 Adenoviral Vectors
7.1.5 Adeno-Associated Viral (AAV) Vectors
7.1.6 Herpes Simplex Viral (HSV) Vectors
7.1.7 Vaccinia Viral Vectors
7.1.8 Others
7.2 North America Viral Vector Manufacturing Market (2017-2032) by Indication Type
7.2.1 Market Overview
7.2.2 Cancer
7.2.3 Genetic Disorders
7.2.4 Infectious Diseases
7.2.5 Cardiovascular Diseases
7.2.6 Neurological Disorders
7.2.7 Others
7.3 North America Viral Vector Manufacturing Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Viral Vector Manufacturing Market (2017-2032)
8.1 Europe Viral Vector Manufacturing Market (2017-2032) by Vector Type
8.1.1 Market Overview
8.1.2 Retroviral Vectors
8.1.3 Lentiviral Vectors
8.1.4 Adenoviral Vectors
8.1.5 Adeno-Associated Viral (AAV) Vectors
8.1.6 Herpes Simplex Viral (HSV) Vectors
8.1.7 Vaccinia Viral Vectors
8.1.8 Others
8.2 Europe Viral Vector Manufacturing Market (2017-2032) by Indication Type
8.2.1 Market Overview
8.2.2 Cancer
8.2.3 Genetic Disorders
8.2.4 Infectious Diseases
8.2.5 Cardiovascular Diseases
8.2.6 Neurological Disorders
8.2.7 Others
8.3 Europe Viral Vector Manufacturing Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Viral Vector Manufacturing Market (2017-2032)
9.1 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Vector Type
9.1.1 Market Overview
9.1.2 Retroviral Vectors
9.1.3 Lentiviral Vectors
9.1.4 Adenoviral Vectors
9.1.5 Adeno-Associated Viral (AAV) Vectors
9.1.6 Herpes Simplex Viral (HSV) Vectors
9.1.7 Vaccinia Viral Vectors
9.1.8 Others
9.2 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Indication Type
9.2.1 Market Overview
9.2.2 Cancer
9.2.3 Genetic Disorders
9.2.4 Infectious Diseases
9.2.5 Cardiovascular Diseases
9.2.6 Neurological Disorders
9.2.7 Others
9.3 Asia Pacific Viral Vector Manufacturing Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Viral Vector Manufacturing Market (2017-2032)
10.1 Latin America Viral Vector Manufacturing Market (2017-2032) by Vector Type
10.1.1 Market Overview
10.1.2 Retroviral Vectors
10.1.3 Lentiviral Vectors
10.1.4 Adenoviral Vectors
10.1.5 Adeno-Associated Viral (AAV) Vectors
10.1.6 Herpes Simplex Viral (HSV) Vectors
10.1.7 Vaccinia Viral Vectors
10.1.8 Others
10.2 Latin America Viral Vector Manufacturing Market (2017-2032) by Indication Type
10.2.1 Market Overview
10.2.2 Cancer
10.2.3 Genetic Disorders
10.2.4 Infectious Diseases
10.2.5 Cardiovascular Diseases
10.2.6 Neurological Disorders
10.2.7 Others
10.3 Latin America Viral Vector Manufacturing Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Viral Vector Manufacturing Market (2017-2032)
11.1 Middle East and Africa Viral Vector Manufacturing Market (2017-2032) by Vector Type
11.1.1 Market Overview
11.1.2 Retroviral Vectors
11.1.3 Lentiviral Vectors
11.1.4 Adenoviral Vectors
11.1.5 Adeno-Associated Viral (AAV) Vectors
11.1.6 Herpes Simplex Viral (HSV) Vectors
11.1.7 Vaccinia Viral Vectors
11.1.8 Others
11.2 Middle East and Africa Viral Vector Manufacturing Market (2017-2032) by Indication Type
11.2.1 Market Overview
11.2.2 Cancer
11.2.3 Genetic Disorders
11.2.4 Infectious Diseases
11.2.5 Cardiovascular Diseases
11.2.6 Neurological Disorders
11.2.7 Others
11.3 Middle East and Africa Viral Vector Manufacturing Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Lonza Group AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Thermo Fisher Scientific Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Catalent, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Merck KGaA (MilliporeSigma)
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 FUJIFILM Diosynth Biotechnologies
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 WuXi AppTec Co., Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Cobra Biologics (Acquired by Pall Corporation)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 VGXI, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Sartorius AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Kaneka Eurogentec S.A.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Vigene Biosciences, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Oxford Biomedica plc
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Cell and Gene Therapy Catapult
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Rentschler Biopharma SE
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 4D Molecular Therapeutics
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Viral Vector Manufacturing Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings